CNS Pharmaceuticals to Present at Two Investor Conferences in April

Rhea-AI Summary

CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) announced CEO John Climaco will present at two investor conferences in April. The company focuses on treatments for brain and CNS cancers. The presentations will be at the MedInvest Biotech & Pharma Investor Conference on April 4 and the 14th Annual LD Micro Invitational on April 9.

HOUSTON, TX / ACCESSWIRE / April 1, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that John Climaco, Chief Executive Officer of CNS Pharmaceuticals will present at two upcoming investor conferences being held in New York City in April.

In addition to the presentations, management will be available to participate in one-on-one meetings with qualified members of the investor community who are registered to attend the respective conferences.

Details of the presentations are as follows:

• MedInvest Biotech & Pharma Investor Conference
  • Date: Thursday, April 4, 2024
  • Time: 4:25 PM ET
  • A live webcast of the event will be available on the Events page of the Investors section of the Company's website (www.cnspharma.com).
• 14th Annual LD Micro Invitational
  • Date: Tuesday, April 9, 2024
  • Time: 1:00 PM ET
  • Interested parties are invited to register to watch the presentation virtually here: https://ldinv14.sequireevents.com/

About CNS Pharmaceuticals, Inc.

CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The Company's lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer.

For more information, please visit www.CNSPharma.com, and connect with the Company on Twitter, Facebook, and LinkedIn.

CONTACTS:

Investor Relations Contact
JTC Team, LLC
Jenene Thomas
833-475-8247
CNSP@jtcir.com

SOURCE: CNS Pharmaceuticals, Inc.

View the original press release on accesswire.com

FAQ

When will John Climaco present at the MedInvest Biotech & Pharma Investor Conference?

John Climaco will present on Thursday, April 4, 2024, at 4:25 PM ET.

Where can the live webcast of the event be accessed?

The live webcast will be available on the Events page of the Investors section of CNS Pharmaceuticals' website.

When is the 14th Annual LD Micro Invitational presentation scheduled?

The presentation at the 14th Annual LD Micro Invitational is scheduled for Tuesday, April 9, 2024, at 1:00 PM ET.

How can interested parties register to watch the LD Micro Invitational presentation virtually?

Interested parties can register to watch the presentation virtually at https://ldinv14.sequireevents.com/